Read + Share
Gelissen LMY, Hogenboom L, Toorop AA, Strijbis EMM, et al. Wearing-off symptoms persist in the majority of patients with multiple sclerosis
after switching from natalizumab to ocrelizumab. J Neurol Sci 2025;479:125652.
PMID: 41237452
|
 |
|
Gelissen LMY, Hogenboom L, Toorop AA, Strijbis EMM, et al. Wearing-off symptoms persist in the majority of patients with multiple sclerosis
after switching from natalizumab to ocrelizumab. J Neurol Sci 2025;479:125652.
PMID: 41237452
|
|
|
|